Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-05-02
2010-06-01
Jiang, Shaojia Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S019300, C514S061000
Reexamination Certificate
active
07727962
ABSTRACT:
The present invention concerns powders containing a pharmaceutical active substance and a combination of excipients comprising at least one 1,4 O-linked saccharose derivative selected from the compounds: 1,4 O-linked D-Gal-saccharose (lactosucrose), 1,4 O-linked D-Glu-saccharose (glucosyl sucrose), or 1,4 O-linked Glu-Glu-saccharose (maltosyl sucrose) in combination with at least one further excipient. The other excipient is preferably an amino acid, a peptide and/or a mono-, di- and/or oligosaccharide, wherein the oligosaccharide may be a second 1,4 O-linked saccharose derivative, provided that this is different from the first.
REFERENCES:
patent: 3634582 (1972-01-01), Hartley et al.
patent: 3894146 (1975-07-01), Tsuyama
patent: 3906950 (1975-09-01), Cocozza
patent: 4013075 (1977-03-01), Cocozza
patent: 4570630 (1986-02-01), Elliott et al.
patent: 4811731 (1989-03-01), Newell et al.
patent: 5035237 (1991-07-01), Newall et al.
patent: 5296473 (1994-03-01), Hara et al.
patent: 5320094 (1994-06-01), Laube et al.
patent: 5458135 (1995-10-01), Patton et al.
patent: 5489577 (1996-02-01), Ikeda et al.
patent: 5505945 (1996-04-01), Gristina et al.
patent: 5522385 (1996-06-01), Lloyd et al.
patent: 5626874 (1997-05-01), Conte et al.
patent: 5672581 (1997-09-01), Rubsamen et al.
patent: 5753469 (1998-05-01), Nakada et al.
patent: 5785049 (1998-07-01), Smith et al.
patent: 5922324 (1999-07-01), Aga et al.
patent: 5947118 (1999-09-01), Hochrainer et al.
patent: 5972388 (1999-10-01), Sakon et al.
patent: 6453795 (2002-09-01), Eicher et al.
patent: 2003/0059511 (2003-03-01), Ishii
patent: 2005/0250705 (2005-11-01), Bassarab et al.
patent: 2005/0255119 (2005-11-01), Bassarab et al.
patent: 2006/0008574 (2006-01-01), Begli et al.
patent: 2273241 (1998-07-01), None
patent: 2273277 (1998-07-01), None
patent: 2297174 (1999-02-01), None
patent: 2565019 (2005-12-01), None
patent: 1792207 (1971-11-01), None
patent: 3625685 (1987-03-01), None
patent: 19732351 (1999-02-01), None
patent: 19953727 (2001-05-01), None
patent: 129985 (1985-01-01), None
patent: 237507 (1987-09-01), None
patent: 467172 (1992-01-01), None
patent: 00630651 (1994-12-01), None
patent: 0739986 (1996-10-01), None
patent: 0745382 (1996-12-01), None
patent: 0911037 (1999-04-01), None
patent: 0974358 (2000-01-01), None
patent: 1174148 (2002-01-01), None
patent: 1223175 (2002-07-01), None
patent: 11297 (1989-11-01), None
patent: 13328 (1990-11-01), None
patent: 14468 (1991-10-01), None
patent: 07607 (1994-04-01), None
patent: 28958 (1994-12-01), None
patent: 31479 (1995-11-01), None
patent: 09814 (1996-04-01), None
patent: 32096 (1996-10-01), None
patent: 32149 (1996-10-01), None
patent: 04801 (1997-02-01), None
patent: 12683 (1997-04-01), None
patent: 12687 (1997-04-01), None
patent: 20590 (1997-06-01), None
patent: 41031 (1997-11-01), None
patent: 41833 (1997-11-01), None
patent: 44013 (1997-11-01), None
patent: 16205 (1998-04-01), None
patent: WO 98/16205 (1998-04-01), None
patent: 31346 (1998-07-01), None
patent: 07340 (1999-02-01), None
patent: 99/27071 (1999-06-01), None
patent: 66903 (1999-12-01), None
patent: 00/09164 (2000-02-01), None
patent: 10541 (2000-03-01), None
patent: 13893 (2000-03-01), None
patent: 00263 (2001-01-01), None
patent: 32144 (2001-10-01), None
patent: 43750 (2002-06-01), None
patent: 03/041512 (2003-05-01), None
patent: 03/064473 (2003-08-01), None
patent: 03/080027 (2003-10-01), None
patent: 104473 (2003-12-01), None
patent: 112996 (2005-12-01), None
G. Xie, et al., “The thermodynamic mechanism of protein stabilization by trehalose”. Biophysical Chemistry, vol. 64, No. 1, 1997, pp. 25-43.
G. Xie, et al., “Mechanism of the stabilization of ribonuclease A by sorbitol: Preferential hydration is greater for the denatured than for the native protein”. Protein Science, vol. 6, 1997, pp. 211-221.
S. N. Timasheff. “The control of protein stability and association by weak interactions with water: How do solvents affect these processes?”. Annual Rev. Biophysics and Biomolecular Structure, vol. 22, 1993, pp. 67-97.
A. M. Boctor, et al., “Enhancement of the stability of thrombin by polyols: microcalorimetric studies”. Journal of Pharmacy and Pharmacology, vol. 44, No. 7, 1992, pp. 600-603.
B. S. Chang, et al., “Stablization of lyophilized porcine pancreatic elastase”. Pharmaceutical Research, vol. 10, No. 10, 1993, pp. 1478-1483.
A. C. Herman, et al., “Characterization, formulation, and stability of neupogen (Filgrastim), a recombinant human granulocyte-colony stimulating factors”. Pharmaceutical Biotechnology, vol. 9, 1996, pp. 303-328.
H.K. Chan, et al., “Effects of additives on heat denaturation of rhDNase in solutions”. Pharmaceutical Research, vol. 13, No. 5, 1996, pp. 756-761.
J. Zhang, et al., “NMR study of the cold, heat, and pressure unfolding of ribonuclease A”. Biochemistry, 1995, vol. 34, No. 27, pp. 8631-8641.
R. L. Remmele, Jr., et al., “Interleukin-1 receptor (IL-1R) liquid formulation development using differential scanning calorimetry”. Pharmaceutical Research, vol. 15, No. 2, 1998, pp. 200-208.
Y. F. Maa, et al., “Effect of spray drying and subsequent processing conditions on residual moisture content and physical/biochemical stability of protein inhalation powders”. Pharmaceutical Research, vol. 15, No. 5, 1998, pp. 768-775.
J. Broadhead, et al., “The effect of process and formulation variables on the properties of spray-dried b-galactosidase”. Journal Pharm. Pharmacol, 1994, vol. 46, No. 6, pp. 458-467.
M. T. Vidgren, et al., “Comparison of physical and inhalation properties of spray-dried and mechanically micronized disodium cromoglycate”. Int. J. Pharmaceutics, vol. 35, 1987, pp. 139-144.
R. W. Niven, et al., “Pulmonary delivery of powders and solutions containing recombinant human granulocyte colony-stimulating factor (rhG-CSF) to the rabbit”. Pharmaceutical Research, vol. 11, No. 8, 1994, pp. 1101-1109.
Y. F. Maa, et al., “The effect of operating and formulation variables on the morphology of spray-dried protein particles”. Pharmaceutical Development and Technology, vol. 2, No. 3, 1997, pp. 213-223.
H. R. Costantino, et al., “Effect of mannitol crystallization on the stability and aerosol performance of a spray-dried pharmaceutical protein, recombinant humanized anti-IgE monoclonal antibody”. Journal of Pharmaceutical Sciences, Vo.87, No. 11, 1998, pp. 1406-1411.
C. Bosquillon, et al., “Influence of formation excipients and physical characteristics of inhalation dry powders on their aerosolization performance”. Journal of Controlled Release, vol. 70, No. 3, 2001, pp. 329-339.
J. S. Huston, et al., “Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced inEscherichia Coli”. Proc. Natl. Acad. Sci., USA, vol. 85, 1988, pp. 5879 ff.
O. Perisic, et al., “Crystal structure of a diabody, a bivalent antibody fragment”. Structure, vol. 2, 1994, pp. 1217 ff.
S. Z. Hu., et al., “Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts”. Cancer Research, vol. 56, 1996, pp. 3055 ff.
A. A. Kortt, et al., “Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five-and ten-residue linkers form dimmers and with zero-residue linker a trimer”. Protein Engineering, vol. 10, No. 4, 1997, pp. 423 ff.
B. Lovejoy, et al. “Crystal structure of a synthetic triple-standard a-Helical bundle”. Science, vol. 259, 1993, pp. 1288 ff.
P. Pack, et al., “Tetravalent miniantibodies with high avidity assembling inEscherichia coli”. Journal Mo. Biol., 1995, 1995, 246, p. 28-34.
P. Pack, et al., “Improved bivalent miniantibodies, with identical avidy as whole antibodies, produced by high cell density fermentation ofEscherichia c
Bassarab Stefan
Bechtold-Peters Karoline
Friess Wolfgang
Fuhrherr Richard
Garidel Patrick
Boehringer Ingelheim Pharma GmbH & Co. KG
Bottino Anthony P.
Devlin Mary-Ellen M.
Jiang Shaojia Anna
Krishnan Ganapathy
LandOfFree
Powder comprising new compositions of oligosaccharides and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Powder comprising new compositions of oligosaccharides and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Powder comprising new compositions of oligosaccharides and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4157574